title: Death receptors as targets in cancer.
abstract: Anti-tumour therapies based on the use pro-apoptotic receptor agonists, including TNF-related apoptosis-inducing ligand (TRAIL) or monoclonal antibodies targeting TRAIL-R1 or TRAIL-R2, have been disappointing so far, despite clear evidence of clinical activity and lack of adverse events for the vast majority of these compounds, whether combined or not with conventional or targeted anti-cancer therapies. This brief review aims at discussing the possible reasons for the lack of apparent success of these therapeutic approaches and at providing hints in order to rationally design optimal protocols based on our current understanding of TRAIL signalling regulation or resistance for future clinical trials.
  
  
  BACKGROUND
  This article is part of a themed section on Emerging Therapeutic Aspects in Oncology. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2013.169.issue-8.
authors: UMR866, INSERM, Dijon, France. olivier.micheau@inserm.fr
authors: O
authors: O
authors: Micheau
authors: S
authors: S
authors: Shirley
authors: F
authors: F
authors: Dufour
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D061067:Antibodies, Monoclonal, Humanized / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D051017:Apoptosis Regulatory Proteins / Q000187:drug effects; D053418:Death Domain Receptor Signaling Adaptor Proteins / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D053218:Receptors, Death Domain / Q000187:drug effects*; D011994:Recombinant Proteins; D053221:TNF-Related Apoptosis-Inducing Ligand / Q000187:drug effects / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D051017:Apoptosis Regulatory Proteins; D053418:Death Domain Receptor Signaling Adaptor Proteins; D053218:Receptors, Death Domain; D011994:Recombinant Proteins; D053221:TNF-Related Apoptosis-Inducing Ligand; C505653:TNFSF10 protein, human; C554537:conatumumab; C552861:tigatuzumab; C510234:lexatumumab; C548876:drozitumab
keywords: Fas; TNF-receptor superfamily; TRAIL; apoptosis; resistance; therapy; tumour targeting
references: Cancer. 2008 Jul 1;113(1):135-42
references: 18457325
references: Prostate. 2005 Feb 1;62(2):165-86
references: 15389801
references: Cancer Invest. 2011 Oct;29(8):511-20
references: 21877938
references: Cell Death Differ. 2004 Jul;11 Suppl 1:S86-96
references: 15105837
references: Mol Cancer Ther. 2007 Apr;6(4):1387-99
references: 17431117
references: J Clin Oncol. 2010 Jun 10;28(17):2839-46
references: 20458040
references: Clin Cancer Res. 2002 Dec;8(12):3734-40
references: 12473583
references: Clin Cancer Res. 2010 Dec 1;16(23):5734-49
references: 20940278
references: EMBO J. 2007 Feb 21;26(4):1055-67
references: 17268552
references: Cancer Res. 2000 Jun 1;60(11):3051-7
references: 10850456
references: Clin Cancer Res. 2010 Feb 15;16(4):1256-63
references: 20145186
references: Clin Cancer Res. 2008 Dec 1;14(23):7733-40
references: 19047100
references: Leuk Res. 2004 Apr;28(4):359-65
references: 15109535
references: Oncogene. 2003 Mar 27;22(12):1807-16
references: 12660816
references: Mol Cancer Ther. 2009 Oct;8(10):2969-80
references: 19808976
references: Mol Cancer Ther. 2005 Dec;4(12):2026-36
references: 16373718
references: Gynecol Oncol. 2001 Jun;81(3):380-90
references: 11371126
references: Biochemistry. 2009 Mar 17;48(10):2180-91
references: 19236007
references: Cancer. 1994 Apr 15;73(8):2013-26
references: 8156506
references: Clin Adv Hematol Oncol. 2005 Aug;3(8):635-42, 662
references: 16167050
references: Eur J Cancer. 2012 Mar;48(4):547-63
references: 22240283
references: Clin Cancer Res. 2010 Nov 15;16(22):5529-38
references: 20889918
references: Zhonghua Zhong Liu Za Zhi. 2008 Nov;30(11):808-12
references: 19173823
references: J Surg Oncol. 2012 May;105(6):563-9
references: 22020863
references: Zhonghua Yi Xue Za Zhi. 2005 Aug 3;85(29):2021-5
references: 16313792
references: Br J Cancer. 2003 Jul 7;89(1):206-14
references: 12838325
references: Mol Cell Biol. 2005 Mar;25(5):2000-13
references: 15713653
references: Clin Cancer Res. 2009 Sep 1;15(17):5584-90
references: 19690193
references: Mol Cell Biol. 2003 Feb;23(4):1428-40
references: 12556501
references: Oncogene. 2008 Jul 10;27(30):4161-71
references: 18345033
references: Cancer Lett. 2010 Jan 1;287(1):98-108
references: 19577358
references: Ann Oncol. 2010 Feb;21(2):376-381
references: 19633048
references: Clin Lung Cancer. 2014 May;15(3):188-196.e2
references: 24560012
references: Blood. 2008 Nov 1;112(9):3807-17
references: 18599795
references: Cancer Res. 2012 Sep 1;72(17):4562-73
references: 22738917
references: Clin Cancer Res. 2008 Jun 1;14(11):3450-5
references: 18519776
references: Cancer Res. 2005 Dec 15;65(24):11265-70
references: 16357130
references: Biochem Biophys Res Commun. 2008 Aug 8;372(4):870-4
references: 18534188
references: J Neurooncol. 2006 Jun;78(2):161-71
references: 16544055
references: FEBS Lett. 2002 Nov 6;531(2):304-8
references: 12417331
references: J Clin Oncol. 2007 Apr 10;25(11):1390-5
references: 17416859
references: Mol Cell. 2009 Dec 11;36(5):831-44
references: 20005846
references: Cancer Lett. 2004 Aug 10;211(2):189-97
references: 15219942
references: Endocr Relat Cancer. 2009 Jun;16(2):443-53
references: 19321593
references: J Biol Chem. 2005 Jun 17;280(24):22856-67
references: 15757891
references: Haematologica. 2005 May;90(5):612-24
references: 15921376
references: Oncogene. 2006 Aug 7;25(34):4798-811
references: 16892092
references: Nat Med. 2007 Sep;13(9):1070-7
references: 17767167
references: Gastroenterology. 2011 Aug;141(2):663-73
references: 21683075
references: J Clin Invest. 1999 Jul;104(2):155-62
references: 10411544
references: Cancer Res. 1999 Dec 15;59(24):6153-8
references: 10626806
references: Biochemistry. 2000 Feb 1;39(4):633-40
references: 10651627
references: Br J Cancer. 2011 Dec 6;105(12):1830-8
references: 22033270
references: Nature. 1989 Dec 7;342(6250):705-8
references: 2531845
references: Acta Pharmacol Sin. 2005 Nov;26(11):1373-81
references: 16225761
references: J Mol Med (Berl). 2009 Oct;87(10):995-1007
references: 19680616
references: Gynecol Oncol. 2007 Oct;107(1):14-21
references: 17604087
references: Cell Death Differ. 2012 Sep;19(9):1482-94
references: 22421964
references: J Exp Clin Cancer Res. 2009 Feb 20;28:24
references: 19232089
references: Haematologica. 2012 Jan;97(1):38-46
references: 21933852
references: Clin Cancer Res. 2008 Aug 15;14(16):5090-8
references: 18698026
references: Blood. 1998 Apr 15;91(8):2991-7
references: 9531611
references: Mol Cell Proteomics. 2012 Mar;11(3):M111.013730
references: 22213832
references: Nat Med. 1999 Feb;5(2):157-63
references: 9930862
references: Cell Death Differ. 2010 Mar;17(3):551-61
references: 19798106
references: Lung Cancer. 2009 Jul;65(1):98-104
references: 19081160
references: Expert Opin Ther Targets. 2007 Oct;11(10):1299-314
references: 17907960
references: Mol Cell Biol. 2006 Oct;26(19):7046-55
references: 16980609
references: Clin Cancer Res. 2011 May 15;17(10):3181-92
references: 21385927
references: Oncogene. 2003 Dec 8;22(56):9030-40
references: 14663481
references: Cell. 2012 May 11;149(4):780-94
references: 22579283
references: Cell Death Differ. 2005 Jul;12(7):773-82
references: 15861184
references: Cancer Res. 1994 Sep 15;54(18):4855-78
references: 8069852
references: J Clin Oncol. 2011 Nov 20;29(33):4442-51
references: 22010015
references: Oncogene. 2003 Apr 3;22(13):2034-44
references: 12673208
references: Oncogene. 2000 Mar 30;19(14):1735-43
references: 10777207
references: Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2006 Dec;14(6):1123-8
references: 17204177
references: Cancer Res. 2007 Jun 1;67(11):5397-407
references: 17545621
references: Cell. 2003 Jul 25;114(2):181-90
references: 12887920
references: Clin Cancer Res. 2009 Mar 15;15(6):2031-8
references: 19276268
references: Drug Resist Updat. 2004 Apr;7(2):139-56
references: 15158769
references: Recent Pat Anticancer Drug Discov. 2011 Sep;6(3):311-23
references: 21756247
references: Br J Haematol. 2007 Nov;139(4):568-77
references: 17922877
references: J Immunol. 2001 Apr 15;166(8):4891-8
references: 11290766
references: Clin Cancer Res. 2006 Apr 15;12(8):2640-6
references: 16638878
references: Cancer Res. 2005 Oct 15;65(20):9169-75
references: 16230375
references: Clin Cancer Res. 2007 Oct 15;13(20):6187-94
references: 17947486
references: Cancer Res. 2004 Aug 1;64(15):5078-83
references: 15289308
references: Clin Cancer Res. 2010 Dec 1;16(23):5883-91
references: 20947515
references: Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008 Oct;16(5):1055-9
references: 18928594
references: Gynecol Oncol. 2010 Mar;116(3):549-55
references: 19959214
references: Ann Oncol. 2008 Jun;19(6):1060-7
references: 18304965
references: Cancer Res. 2004 Sep 15;64(18):6666-72
references: 15374982
references: Cancer Invest. 2012 Dec;30(10):727-31
references: 23061802
references: Cell Mol Life Sci. 2010 Sep;67(18):3115-30
references: 20508968
references: Neuro Oncol. 2010 Jul;12(7):687-700
references: 20511188
references: J Clin Oncol. 2012 Nov 20;30(33):4141-7
references: 23071222
references: Br J Cancer. 2010 Feb 2;102(3):506-12
references: 20068564
references: Br J Cancer. 2000 Feb;82(4):973-80
references: 10732774
references: Nature. 1993 Aug 26;364(6440):806-9
references: 7689176
references: Cell Death Differ. 2007 Dec;14(12):2021-34
references: 17703232
references: J Surg Oncol. 2009 Oct 1;100(5):396-400
references: 19582795
references: Cancer Res. 1999 Feb 1;59(3):734-41
references: 9973225
references: Cancer Res. 2007 May 15;67(10):4981-8
references: 17510429
references: Curr Biol. 1997 Dec 1;7(12):1003-6
references: 9382840
references: Br J Cancer. 2010 Dec 7;103(12):1783-7
references: 21081929
references: J Clin Oncol. 2010 Mar 20;28(9):1527-33
references: 20159815
references: Nat Med. 2002 Mar;8(3):274-81
references: 11875499
references: Cancer Gene Ther. 2007 Dec;14(12):976-84
references: 17853923
references: Mol Cell. 1999 Oct;4(4):563-71
references: 10549288
references: Oncogene. 2002 Apr 4;21(15):2283-94
references: 11948412
references: Ann Oncol. 2012 Nov;23(11):2834-2842
references: 22700995
references: J Biol Chem. 2000 Jul 7;275(27):20632-7
references: 10748154
references: Oncogene. 2008 Oct 9;27(46):6012-22
references: 18560353
references: Cancer Res. 2004 Jul 15;64(14):4900-5
references: 15256461
references: Clin Cancer Res. 2005 Jul 15;11(14):5188-94
references: 16033835
references: Mol Ther. 2000 Feb;1(2):130-44
references: 10933923
references: Oncotarget. 2011 Oct;2(10):739-51
references: 22036896
references: Cancer Res. 2004 Dec 15;64(24):9105-14
references: 15604280
references: Cancer Res. 2010 Feb 1;70(3):1101-10
references: 20103630
references: J Clin Oncol. 2009 Sep 10;27(26):4413-21
references: 19652058
references: Lung Cancer. 2008 Jul;61(1):82-90
references: 18255187
references: Clin Cancer Res. 2009 Jan 15;15(2):650-9
references: 19147771
references: Science. 1998 Aug 28;281(5381):1305-8
references: 9721089
references: Int J Radiat Oncol Biol Phys. 2008 Jun 1;71(2):507-16
references: 18474311
references: Ann Surg Oncol. 2010 Nov;17(11):3000-7
references: 20429035
references: Appl Immunohistochem Mol Morphol. 2002 Sep;10(3):210-7
references: 12373145
references: Nat Genet. 1997 Oct;17(2):141-3
references: 9326928
references: Eur J Cancer. 2008 Oct;44(15):2312-8
references: 18755584
references: Cancer Res. 2004 Jun 1;64(11):3922-7
references: 15173003
references: MAbs. 2009 Nov-Dec;1(6):552-62
references: 20068388
references: Mol Cell Biol. 2001 Aug;21(16):5299-305
references: 11463813
references: Cell Death Differ. 2010 Jun;17(6):942-51
references: 20019748
references: Cancer Biother Radiopharm. 2010 Feb;25(1):13-9
references: 20187792
references: Br J Haematol. 2013 Jan;160(2):188-98
references: 23167276
references: J Exp Med. 1998 Apr 20;187(8):1205-13
references: 9547332
references: Neuro Oncol. 2011 Feb;13(2):155-64
references: 21183510
references: PLoS One. 2011;6(5):e19679
references: 21625476
references: Cancer J. 2006 Jul-Aug;12(4):257-73
references: 16925970
references: Proc Natl Acad Sci U S A. 2006 Jun 6;103(23):8634-9
references: 16731632
references: J Mol Med (Berl). 2010 Jul;88(7):729-40
references: 20354842
references: Cancer Chemother Pharmacol. 2011 Sep;68(3):733-41
references: 21161528
references: Nat Med. 2001 Apr;7(4):383-5
references: 11283636
references: J Clin Oncol. 2006 Nov 1;24(31):4998-5004
references: 17075118
references: Hematology. 2011 Nov;16(6):341-50
references: 22183068
references: Cell Death Differ. 2011 Apr;18(4):700-11
references: 21072058
references: Int J Cancer. 2002 Jun 1;99(4):491-504
references: 11992538
references: Nat Med. 1998 Apr;4(4):408-14
references: 9546785
references: Cell Death Differ. 2003 Sep;10(9):997-1004
references: 12934074
references: Cancer Lett. 2010 Nov 28;297(2):155-64
references: 20605676
references: J Clin Oncol. 2008 Jul 20;26(21):3621-30
references: 18640940
references: Cancer Res. 2007 Sep 1;67(17):8274-84
references: 17804742
references: Cancer Res. 2003 Sep 1;63(17):5390-400
references: 14500373
references: Oncogene. 2004 Oct 28;23(50):8320-32
references: 15467752
references: J Invest Dermatol. 2005 Nov;125(5):1010-9
references: 16297203
references: Nat Med. 2000 May;6(5):564-7
references: 10802713